Preferred Label : obeticholic acid;
MeSH note : a farnesoid X receptor agonist and anticholestatic agent; structure in first source;
CISMeF synonym : INT 747;
MeSH synonym : 6-ECDCA; 6-ethyl-3,7-dihydroxycholan-24-oic acid; 6ECDCA; 6-ethyl chenodeoxycholic acid; cholan-24-oic acid, 6-ethyl-3,7-dihydroxy-, (3alpha,5beta,6alpha,7alpha)-; 6alpha-ethyl-3alpha,7alpha-dihydroxy-5beta-cholan-24-oic acid; 6alpha-ethyl-chenodeoxycholic acid; 6-ethylchenodeoxycholic acid;
MeSH hyponym : DSP1747; INT747; INT-747;
Is substance : O;
UNII : 0462Z4S4OZ;
Origin ID : C464660;
UMLS CUI : C1143018;
ATC code(s)
CISMeF manual mappings
MeSH term(s) associated for indexing
Record concept(s)
See also inter- (CISMeF)
Semantic type(s)
UMLS correspondences (same concept)
Validated automatic mappings to BTNT
https://ansm.sante.fr/informations-de-securite/ocaliva-acide-obeticholique-recommandation-dabrogation-de-lautorisation-de-mise-sur-le-marche-conditionnelle-dans-lunion-europeenne-en-raison-dun-benefice-clinique-non-confirme
2024
false
false
false
France
French
risk assessment
Benefit-Risk assessment
drug information
obeticholic acid
obeticholic acid
obeticholic acid
Primary Biliary Cholangitis
---
OCALIVA (obeticholic acid) – New Contraindication for the Treatment of Primary Biliary
Cholangitis (PBC)
https://recalls-rappels.canada.ca/fr/avis-rappel/ocaliva-acide-obeticholique-nouvelle-contre-indication-pour-traitement-cholangite
2022
false
false
false
Canada
French
English
pharmacovigilance note
administration, oral
obeticholic acid
Primary Biliary Cholangitis
---
https://ansm.sante.fr/informations-de-securite/ocalivav-acide-obeticholique-nouvelle-contre-indication-pour-le-traitement-de-la-cholangite-biliaire-primitive-cbp-chez-les-patients-presentant-une-cirrhose-hepatique-decompensee-ou-des-antecedents-de-decompensation-hepatique
2022
false
false
false
France
French
pharmacovigilance note
Primary Biliary Cholangitis
obeticholic acid
Hepatic decompensation
obeticholic acid
guidelines for drug use
---
https://www.has-sante.fr/jcms/p_3186712/fr/ocaliva
2020
false
false
false
France
obeticholic acid
adult
insurance, health, reimbursement
treatment outcome
drug therapy, combination
ursodeoxycholic acid
Primary biliary cholangitis
Primary Biliary Cholangitis
administration, oral
evaluation of the transparency committee
obeticholic acid
chenodeoxycholic acid
liver cirrhosis, biliary
chenodeoxycholic acid
chenodeoxycholic acid
---
https://ansm.sante.fr/informations-de-securite/ocaliva-r-v-acide-obeticholique-renforcement-de-ladaptation-posologique-chez-les-patients-atteints-de-cholangite-biliaire-primitive-cbp-avec-insuffisance-hepatique-moderee-a-severe
2018
false
false
false
France
French
guidelines for drug use
pharmacovigilance note
administration, oral
obeticholic acid
cholangitis
Primary cholangitis (disorder)
hepatic insufficiency
continuity of patient care
liver function tests
Hepatic decompensation
disease progression
Child-Pugh score class A (finding)
Child-Pugh score class B (finding)
Child-Pugh score class C (finding)
obeticholic acid
drug monitoring
obeticholic acid
chenodeoxycholic acid
chenodeoxycholic acid
chenodeoxycholic acid
---
https://www.has-sante.fr/portail/jcms/c_2773278/fr/ocaliva
https://www.has-sante.fr/portail/jcms/c_2773278/fr/ocaliva-acide-obeticholique-acide-biliaire
2017
false
false
false
France
French
treatment outcome
orphan drug production
cholangitis
Primary cholangitis (disorder)
obeticholic acid
obeticholic acid
adult
drug therapy, combination
ursodeoxycholic acid
administration, oral
evaluation of the transparency committee
guidelines for drug use
chenodeoxycholic acid
chenodeoxycholic acid
---
obeticholic acid
https://www.ema.europa.eu/medicines/human/EPAR/Ocaliva
2016
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
orphan drug production
drug approval
europe
cholangitis
Primary cholangitis (disorder)
obeticholic acid
obeticholic acid
obeticholic acid
adult
drug therapy, combination
ursodeoxycholic acid
administration, oral
risk assessment
pregnancy
breast feeding
drug interactions
product surveillance, postmarketing
drug evaluation, preclinical
chenodeoxycholic acid
chenodeoxycholic acid
chenodeoxycholic acid
---